Barclays lowered the firm’s price target on Arvinas (ARVN) to $16 from $32 and keeps an Overweight rating on the shares. The firm says Pfizer reduced vepdeg development while the company’s cash runway is extended to the second half of 2028 on workforce reduction. It has “further derisked” the model, but still sees upside.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Reports Strong Q1 2025 Results and Strategic Shift
- Arvinas downgraded to Hold at Jefferies after Vepdeg development decision
- Arvinas downgraded to Hold from Buy at Jefferies
- Oppenheimer surprised by ‘hasty’ decision to cull frontline Vepdeg development
- Arvinas reports Q1 EPS $1.14 vs (97c) last year